Company research, made clear.

An operating recovery with new CDMO optionality, balanced against commodity exposure and a full valuation.

Commercial CDMO supplies have improved the earnings profile, but repeatability and returns still need proof.

Earlier investments are beginning to pay off, with complex products and biologics supporting a better business mix.

The chemical cycle is improving and new plants are ready to contribute, but capex returns remain the key test.

A strong volume-led quarter and margin stability support growth, while capex conversion and cash discipline remain decisive.

A high-quality consumables franchise with acquisition-led growth, strong cash generation and integration risk.

Fast growth and a move into piping solutions are promising, while debt, working capital and dilution need attention.

A durable electrical franchise with optical-fibre optionality and the strongest risk-adjusted score in the group.

Record operating profit and a deep global order book, with one-off earnings and project execution requiring normalization.

The base API business is recovering strongly, while commodity ibuprofen remains the clearest drag on consolidated margins.

Integrated precision-component capabilities and rising value addition support growth, with capex and working capital to watch.

A high-margin sensing-components niche with electrification tailwinds, balanced against customer-program concentration.

Several profitable automotive platforms now compound together, with OLX India providing the largest monetization runway.

A landmark AI-connectivity award and repaired balance sheet drive an earnings inflection, with execution concentration elevated.

A strategic aerospace moat and exceptional backlog, balanced against delivery timing, supplier dependence and customer concentration.

Acquisition-led scale and major capacity expansion offer growth, while cash conversion, leverage and promoter pledge raise risk.

A weak, lumpy quarter contrasts with exceptional radar backlog and the transformational post-quarter Uttam order.

Global qualifications and high margins support growth, but negative cash flow, tax normalization and valuation demand discipline.

Export-led precision capabilities and Hobel broaden growth, with acquisition comparability, integration and valuation to watch.

Export order momentum, high returns and low debt support compounding, while rapid execution, valuation and dilution need attention.

A fast-growing co-lending NBFC compounds profit at scale, but a thin capital base, rising leverage and modest disclosure keep the quality debate open.

A CDMO-led surge lifted revenue, margin and profit to record levels, but the quarter's mix benefit needs to repeat before it is treated as the new normal.

A spectacular year-on-year profit surge is real, but the sharp sequential decline from an exceptional prior quarter shows how lumpy CDMO-led earnings can be.

Revenue kept growing, but margin compression and lower capacity utilisation pulled profit down sharply, making this a genuinely weak quarter despite top-line growth.

Double-digit growth across both CRO and CDMO segments continued, but the stock's rich valuation left little room for a quarter that did not clearly beat expectations.

Strong year-on-year revenue growth continued, but a sharp sequential profit and margin decline shows the heavy capex cycle's cost pressure has not fully normalized.

Broad-based API growth across immunosuppressants, anti-infectives and oncology, on a debt-free balance sheet, continues a high-quality earnings compounding story.

A major debt-reduction restructuring and the sale of the API/CRAMS business have reshaped the company into a smaller, focused, largely debt-free formulations business.

A 14th straight quarter of record revenue was real, but a non-cash ESOP charge masked the true pace of reported profit growth.

Strong year-on-year growth continued, but a sharp sequential decline from an exceptional prior quarter and a rich ~74x P/E leave limited room for disappointment.

Its strongest quarter in recent years, with export and domestic growth both accelerating, though a rich valuation now assumes this momentum continues.

Record revenue and strong EV/overseas growth were overshadowed by a 28% profit decline and a qualified audit opinion on an ongoing arbitration matter.

Record profit and strong same-store sales growth reflect genuine operating leverage in a large-format electronics retail model, at a still-reasonable valuation.

Balanced domestic and export growth continued a steady compounding trend, with a new expansion plan targeting EV, wind and aerospace applications.

A first-ever quarter above 20% PAT margin reflects a genuine, value-added product mix shift, though the rich valuation already prices in continued execution.

A first-ever ₹400-crore quarter and margin expansion were led by volume growth, with West African backward integration adding a longer-dated raw-material advantage.

Strong consolidated growth, led by the wind engineering business and international operations, came with a modest sequential profit dip and rising finance/employee costs.

Record growth across tyre, rubber and non-rubber segments continued, with a new Dahej plant set to expand capacity, though zinc-price pass-through mechanics keep margins structurally thin.

Steady double-digit growth and margin improvement continued, though the valuation already prices in continued execution.

An exceptional quarter of margin and profit growth was real, but the very rich ~48-65x trailing multiple leaves little room for any moderation in a specialty-coatings niche.

Strong core pharma/chemical-engineering growth continued, but a new, largely unproven AI-datacentre venture is now central to the investment case and a rich ~109x P/E.

Record loan-book growth, nil NPAs and improving returns on assets make this one of the strongest NBFC growth stories in this report set, at a valuation still shy of its own asset-growth pace.

A genuine operational turnaround is underway, with strong Reach Stacker deliveries and an acquisition-led revenue jump, but the company remains net loss-making at the consolidated level.